Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 215,938,800
  • Shares Outstanding, K 2,310,000
  • Annual Sales, $ 53,166 M
  • Annual Income, $ 12,611 M
  • 60-Month Beta 0.67
  • Price/Sales 4.14
  • Price/Cash Flow 11.41
  • Price/Book 2.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.26
  • Number of Estimates 3
  • High Estimate 1.30
  • Low Estimate 1.21
  • Prior Year 1.28
  • Growth Rate Est. (year over year) -1.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.75 +5.51%
on 03/04/19
93.89 -0.27%
on 03/20/19
+3.13 (+3.46%)
since 02/21/19
3-Month
82.07 +14.10%
on 12/27/18
93.89 -0.27%
on 03/20/19
+10.29 (+12.35%)
since 12/21/18
52-Week
72.30 +29.52%
on 06/28/18
93.89 -0.27%
on 03/20/19
+12.56 (+15.49%)
since 03/21/18

Most Recent Stories

More News
Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

AVDL : 1.68 (+4.35%)
JAZZ : 136.53 (+2.22%)
NVS : 93.53 (+0.05%)
TEVA : 16.89 (+0.18%)
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

CNAT : 3.00 (+4.17%)
AGN : 154.32 (+0.42%)
NVS : 93.53 (+0.05%)
PFE : 42.18 (+0.02%)
Atopic Dermatitis Market Highest Growth in Healthcare with Size, Share, Price Trend, Foreseen by 2023

VRX.TO : 30.80 (-3.33%)
ANAC : 99.06 (-0.14%)
AGN : 154.32 (+0.42%)
ALPMF : 15.4350 (+1.88%)
NVS : 93.53 (+0.05%)
REGN : 399.56 (-1.46%)
PFE : 42.18 (+0.02%)
BMY : 48.96 (-0.47%)
Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs

Tilray earnings results speak of bullishness, making things better for marijuana ETF investors.

BUD : 83.27 (-0.19%)
ACT : 25.56 (+0.03%)
TLRY : 70.03 (-0.99%)
NVS : 93.53 (+0.05%)
MJ : 38.13 (-0.63%)
The Worldwide Market for Bone Cancer Treatment to 2024 - Bayer, Amgen, Novartis, and Pfizer Hold Substantial Shares

The "Bone Cancer Treatment Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.

NVS : 93.53 (+0.05%)
Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs

Tilray earnings results speak of bullishness, making things better for marijuana ETF investors.

BUD : 83.27 (-0.19%)
ACT : 25.56 (+0.03%)
TLRY : 70.03 (-0.99%)
NVS : 93.53 (+0.05%)
MJ : 38.13 (-0.63%)
Ocular Inflammation Treatment Market is Anticipated to Reach US$ 500 Billion by 2024

New York, March 19, 2019: Increasing contamination of surroundings by emission of toxins has elevated the risks of ocular inflammation, conjointly referred to as uveitis. Evolving medical technologies...

VRX.TO : 30.80 (-3.33%)
ALIM : 1.10 (-2.65%)
AGN : 154.32 (+0.42%)
NVS : 93.53 (+0.05%)
AKRX : 3.52 (+0.57%)
PFE : 42.18 (+0.02%)
Alnylam's (ALNY) Impressive Pipeline Drives Share Price

Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

MDCO : 27.59 (+2.00%)
ALNY : 89.26 (+0.65%)
NVS : 93.53 (+0.05%)
RHHBY : 33.9400 (-0.44%)
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

AZN : 43.07 (+0.12%)
NVS : 93.53 (+0.05%)
GSK : 41.27 (+1.13%)
BMY : 48.96 (-0.47%)
BioMed Realty Expands Life Science Footprint In San Francisco Bay Area With Campus Acquisition Of The Emeryville Center for Innovation

BioMed Realty, a Blackstone portfolio company, announced today the acquisition of the Emeryville Center for Innovation, located in Emeryville, California, for approximately $135 million. This latest investment...

NVS : 93.53 (+0.05%)
ABBV : 79.42 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 94.49
1st Resistance Point 93.99
Last Price 93.53
1st Support Level 92.88
2nd Support Level 92.27

See More

52-Week High 93.89
Last Price 93.53
Fibonacci 61.8% 85.64
Fibonacci 50% 83.10
Fibonacci 38.2% 80.55
52-Week Low 72.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar